Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 2, 2010, Pages 732-737

  Zhang, Geng ^a   Zhang, Hongtao ^a   Wang, Qiang ^a   Lal, Priti ^a   Carroll, Ann M ^a   De La Llera Moya, Margarita ^b   Xu, Xiaowei ^a   Greene, Mark I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Androgen independent tumor; Antibody therapy; Antibody dependent cellular toxicity; Lipid rafts; Prostate cancer lipid antigen (PCLA)

Indexed keywords

ANDROGEN; GLYCOLIPID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F77; PROSTATE CANCER LIPID ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID RAFT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR;

ANDROGENS; ANIMALS; ANNEXIN A5; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, SURFACE; CELL DIVISION; CELL LINE, TUMOR; EPITHELIAL CELLS; FLOW CYTOMETRY; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; NEOPLASM METASTASIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

MUS MUSCULUS;

EID: 76249129507     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0911397107     Document Type: Article

References (42)

1. Sandblom G, Dufmats M, Nordenskjöld K, Varenhorst E; South-East Region Prostate Cancer Group (2000) Prostate carcinoma trends in three counties in Sweden 1987-1996: results from a population-based national cancer register. Cancer 88:1445-1453.
2. Noldus J, et al. (2000) Stage migration in clinically localized prostate cancer. Eur Urol 38:74-78.
3. Maloney DG, et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
4. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI (1985) Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:697-706.
5. O'Rourke DM, et al. (1998) Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly. Oncogene 16:1197-1207.
6. Bander NH, et al. (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23:4591-4601.
7. Morris MJ, et al. (2005) Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 11:7454-7461.
8. Reiter RE, et al. (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95:1735-1740.
9. Saffran DC, et al. (2001) Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 98:2658-2663.
10. Wente MN, et al. (2005) Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 31:119-125.
11. Carroll AM, et al. (1984) Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen. Clin Immunol Immunopathol 33:268-281.
12. Webber MM, Bello D, Quader S (1997) Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate 30:58-64.
13. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357.
14. Akiyama Y, Lubeck MD, Steplewski Z, Koprowski H (1984) Induction of mouse IgG2a-and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon. Cancer Res 44:5127-5131.
15. Tatituri RV, et al. (2007) Inactivation of Corynebacterium glutamicum NCgl0452 and the role of MgtA in the biosynthesis of a novel mannosylated glycolipid involved in lipomannan biosynthesis. J Biol Chem 282:4561-4572.
16. Paul P, Bordmann A, Rosenfelder G, Towbin H (1992) Simultaneous determination of sugar incorporation into glycosphingolipids and glycoproteins. Anal Biochem 204:265-272.
17. Brown DA, London E (1998) Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14:111-136.
18. Carroll AM, Zalutsky MR, Benacerraf B, Greene MI (1984) Monoclonal antibodies to tissue-associated antigens as antitumor reagents. Surv Synth Pathol Res 3:189-200.
19. Hubert RS, et al. (1999) STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 96:14523-14528.
20. Abe A, et al. (1992) Improved inhibitors of glucosylceramide synthase. J Biochem 111:191-196.
21. Hakomori S (2003) Structure, organization, and function of glycosphingolipids in membrane. Curr Opin Hematol 10:16-24.
22. Nudelman ED, et al. (1988) A novel tumor-associated, developmentally regulated glycolipid antigen defined by monoclonal antibody ACFH-18. J Biol Chem 263:13942-13951.
23. Hakomori S (1984) Tumor-associated carbohydrate antigens. Annu Rev Immunol 2:103-126.
24. Hellström I, Brankovan V, Hellström KE (1985) Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA 82:1499-1502.
25. Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T (2006) A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. Cancer Res 66:5901-5909.
26. Bremer EG, et al. (1984) Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J Biol Chem 259:14773-14777.
27. Mabry M, Speak JA, Griffin JD, Stahel RA, Bernal SD (1985) Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. J Clin Invest 75:1690-1695.
28. Cheung NK, et al. (1985) Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642-2649.
29. Welt S, Carswell EA, Vogel CW, Oettgen HF, Old LJ (1987) Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Clin Immunol Immunopathol 45:214-229.
30. Okada Y, Mugnai G, Bremer EG, Hakomori S (1984) Glycosphingolipids in detergent-insoluble substrate attachment matrix (DISAM) prepared from substrate attachment material (SAM). Their possible role in regulating cell adhesion. Exp Cell Res 155:448-456.
31. Hughes-Jones NC, Gorick BD, Howard JC (1983) The mechanism of synergistic complement-mediated lysis of rat red cells by monoclonal IgG antibodies. Eur J Immunol 13:635-641.
32. Nichols B (2003) Caveosomes and endocytosis of lipid rafts. J Cell Sci 116:4707-4714.
33. Sillence DJ (2007) New insights into glycosphingolipid functions-storage, lipid rafts, and translocators. Int Rev Cytol 262:151-189.
34. Riemann D, et al. (2001) Caveolae/lipid rafts in fibroblast-like synoviocytes: ectopeptidase-rich membrane microdomains. Biochem J 354:47-55.
35. Dalskov SM, et al. (2005) Lipid raft localization of GABA A receptor and Na+, K+ATPase in discrete microdomain clusters in rat cerebellar granule cells. Neurochem Int 46:489-499.
36. Bourrguignon LY, et al. (1995) Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis. J Neurooncol 26:201-208.
37. Allen JA, Halverson-Tamboli RA, Rasenick MM (2007) Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 8:128-140.
38. Carlsson L, Ronquist G, Eliasson R, Egberg N, Larsson A (2006) Flow cytometric technique for determination of prostasomal quantity, size and expression of CD10, CD13, CD26 and CD59 in human seminal plasma. Int J Androl 29:331-338.
39. Utleg AG, et al. (2003) Proteomic analysis of human prostasomes. Prostate 56:150-161.
40. Masuda K, et al. (2006) AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu. Oncogene 25:7740-7746.
41. Svennerholm L, Fredman P (1980) A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta 617:97-109.
42. Xia MQ, Tone M, Packman L, Hale G, Waldmann H (1991) Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 21:1677-1684.